To observe and evaluate the safety and effectiveness of herombopag in the treatment of thrombocytopenia-related diseases in Henan Province
This study is designed as a real-world study on the treatment of thrombocytopenia-related diseases with Herombopag, to observe and analyze the safety and efficacy of Herombopag for thrombocytopenia-related diseases in the real world.
Study Type
OBSERVATIONAL
Enrollment
498
Herombopag in the treatment of thrombocytopenia-related diseases Non-interventional clinical research.Do not interfere with the dosage and market of Hetrobopar Oral medication
Henan Cancer Hospital
Zhengzhou, Henan, China
RECRUITINGIncidence of adverse events after the treatment of Herombopag
The investigator will observe incidence of adverse events after the treatment of Herombopag, including thrombosis, diarrhea, abnormal liver function and so on.
Time frame: From the treatment of Herombopag to 28 days after the end of the medication
Changes of the platelet counts after the treatment of Herombopag
The investigator will assess the changes of the platelet counts after the treatment of Herombopag。
Time frame: From the treatment of Herombopag to 28 days after the end of the medication
Proportion of patients with platelet transfusion
The investigator will assess the proportion of patients with platelet transfusion after the treatment of Herombopag。
Time frame: From the treatment of Herombopag to 28 days after the end of the medication
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.